Retinal Pigment Epithelium Safety Study For Patients In B4711001

General Information

Summary This is a safety follow-up study. Patients enrolled in B4711001 will be followed for a further 4 years with regular visits to assess safety.
Clinical trials phase Long term follow up
Start date (estimated) 2023-05-21
End date (estimated) 2033-05-30
Clinical feature
Label age related macular degeneration
Description A degeneration of macula and posterior pole that is characterized by a loss of vision in the center of the visual field (the macula) resulting from damage to the retina and resulting in blurring of the sharp central vision.; OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number NCT03102138
ICTRP weblink
EudraCT number 2015-002267-42
Other study identifiers
Name B4711005
Source weblink
Study sites
Public contact
Public email
First name Tania
Last name West
Phone +44 20725334112036
United Kingdom
Sponsors Pfizer


Source pluripotent stem cell lines
Which differentiated cell type is used
Label retinal pigment epithelial cell
Description An epithelial cell of the retinal pigmented epithelium.


Recruitment Status Not yet recruiting
Estimated number of participants 10
Contact institutions/departments